Panaxium’s iontronic device is built for neurosurgeons and neurologists to guide precision remapping by delivering unprecedented stimulation directly to the cortex safely, effectively, and selectively, to restore the patient to normalcy following a brain injury or stroke.
Toronto, Canada, and Aix-en-Provence, France, February 10, 2023 – Bioelectronic medicine company Panaxium presented its novel brain machine interface platform for precision remapping at the 2023 Ontario Bioscience Innovation Organization (OBIO) Investment Summit in Toronto, Canada, on February 10, 2023.
Panaxium COO Jonathan Balfour shared the latest developments of the company’s precision cortical therapy, which starts with a patented injury assessment tool that identifies exactly where the injury has occurred, what functions have been disrupted, and identifies optimal remapping location. Panaxium’s iontronic device is built for neurosurgeons and neurologists to “get in and get out” – delivering unprecedented stimulation directly to the cortex, safely, effectively, and selectively, to restore the patient to normalcy.
Ontario Bioscience Innovation Organization (OBIO) is advancing Canada’s competitive edge in health technology innovation and commercialization. Founded in 2009, OBIO is a not-for-profit, membership-based organization engaged in strategy, programming, policy development and advocacy to further the commercialization of Ontario’s human health science companies positioning Ontario as a leader in the international marketplace. OBIO® advances this goal through collaborative partnerships with industry, the investment community, academia, patients and government.
The 2023 OBIO Investment Summit is Canada’s premier health science investment event, a forum that connects global investors with Canada’s best technology innovators. Since 2018 summit companies have raised $1.3 billion.
“It is an honour to be invited by OBIO to present at the 2023 Summit alongside so many incredible innovators,” said Dr. Brad Schmidt, Panaxium CEO and co-founder. “We were proud to have the opportunity to share our ground-breaking technology in the brain computer interface space as well as details on our upcoming acute human trials in Paris, France.”
For more information about Panaxium visit www.panaxium.com. For more information on the 2023 OBIO Investment Summit, read the press release.
Panaxium SAS is a bioelectronic medicine company aiming to fundamentally change the way neurological disease is treated using the advantages of AI-enabled iontronic devices. The company is comprised of a multidisciplinary team of internationally renowned scientists, including world experts in organic bioelectronics and leaders in the fields of chemistry, materials science, electrical engineering, systems design, electronic engineering, data science, biology, biochemistry, and nanotechnology. Together they are working to solve some of the most difficult and important problems in medicine.